Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States.
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Fennec Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RV41's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RV41 exceeded the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: RV41 exceeded the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Fennec Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Fennec Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RV41's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RV41's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RV41 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: RV41 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RV41's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RV41 is overvalued based on its PB Ratio (11.9x) compared to the DE Biotechs industry average (3.2x).
How is Fennec Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RV41 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: RV41 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RV41's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if RV41's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if RV41's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RV41's Return on Equity is forecast to be high in 3 years time
How has Fennec Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RV41 is currently unprofitable.
Growing Profit Margin: RV41 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RV41 is unprofitable, and losses have increased over the past 5 years at a rate of -52.9% per year.
Accelerating Growth: Unable to compare RV41's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RV41 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: RV41 has a negative Return on Equity (-107.58%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Fennec Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RV41's short term assets ($13.9M) exceed its short term liabilities ($2.3M).
Long Term Liabilities: RV41 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RV41 is debt free.
Reducing Debt: RV41 has not had any debt for past 5 years.
Inventory Level: RV41 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if RV41's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RV41 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RV41 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -34.7% each year.
What is Fennec Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RV41's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RV41's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RV41's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RV41's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RV41's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rosty Raykov (43yo)
Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc) since July 2009 and serves as its President. Mr. Ray ...
CEO Compensation Analysis
Compensation vs Market: Rosty's total compensation ($USD1.48M) is above average for companies of similar size in the German market ($USD415.76K).
Compensation vs Earnings: Rosty's compensation has increased whilst the company is unprofitable.
|CEO & Director||10.6yrs||US$1.48m||0.29% $370.8k|
|Chief Financial Officer||4.3yrs||US$863.77k||0.086% $109.4k|
|Chief Commercial Officer||0.4yrs||US$1.23m||no data|
|Controller||4.3yrs||no data||no data|
|President of Pharstat Inc||0yrs||no data||no data|
|Regulatory Consultant||9.8yrs||no data||no data|
|Consultant||0yrs||no data||no data|
Experienced Management: RV41's management team is considered experienced (4.3 years average tenure).
|CEO & Director||10.6yrs||US$1.48m||0.29% $370.8k|
|Independent Director||8.5yrs||US$126.65k||no data|
|Independent Chairman of the Board||4.2yrs||US$190.19k||no data|
|Independent Director||0.4yrs||US$112.43k||no data|
|Independent Director||5.8yrs||US$124.15k||no data|
|Independent Director||3.5yrs||US$124.15k||no data|
Experienced Board: RV41's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.
Fennec Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Fennec Pharmaceuticals Inc.
- Ticker: RV41
- Exchange: DB
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$138.873m
- Listing Market Cap: US$127.652m
- Shares outstanding: 19.90m
- Website: https://www.fennecpharma.com
Number of Employees
- Fennec Pharmaceuticals Inc.
- 68 TW Alexander Drive
- PO Box 13628
- Research Triangle Park
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RV41||BST (Boerse-Stuttgart)||COM NPV||DE||EUR||No data|
|FRX||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Jun 2001|
|RV41||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2001|
|FENC||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Jun 2001|
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 20:38|
|End of Day Share Price||2020/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.